388results about "DsRNA viruses" patented technology

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention provides a recombinant Marek's disease virus co-expressing a Newcastle disease virus F gene and an infectious bursal disease virus supervirulent strain VP2 gene and application thereof, and belongs to the field of genetic engineering vaccines. According to the invention, by using a recombinant cloning technology, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an infectious bursal disease virus super virulent strain VP2 gene is inserted into a spacer region between Marek's disease virus genome UL45 and UL46 genes; according to the method, a recombinant cosmid is constructed and obtained, wherein a Newcastle disease virus F gene and an infectious bursal disease virus super virulent strain VP2 gene expression framework are inserted between Marek's disease virus genome UL45 and UL46 genes, and a recombinant virus C20101 strain co-expressing the Newcastle disease virus F gene and the infectious bursal disease virus super virulent strain VP2 gene is rescued and obtained by the recombinant cosmid. The vaccine prepared from the recombinant Marek's disease virus strain provided by the invention can prevent Newcastle disease, chicken infectious bursal disease and Marek's disease at the same time, and has a good market application prospect.

The invention discloses a self-replicating RNA (Ribonucleic Acid) molecule, a porcine rotavirus RNA vaccine and application thereof, and relates to the technical field of vaccines. According to the present invention, the coding sequence of the porcine rotavirus G9P23 type VP4 protein is optimized, such that the fact that the saRNA prepared by using the nucleotide sequence represented by the SEQ ID NO: 10 can secrete the high porcine rotavirus G9P23 type VP4 protein antigen after the cell transfection is found; after the optimized porcine rotavirus G9P23 type VP4 protein is used for immunizing experimental animals, the level of neutralizing antibodies generated by the animals can be improved, and the challenge protection effect is enhanced. Therefore, the nucleic acid molecule provided by the invention can be used for developing drugs and vaccines for causing protective immune response in experimental animal bodies. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a good application prospect.

The invention relates to the technical field of biological medicine, in particular to a monoclonal antibody of BRVA virus VP7 protein and an epitope and application of the monoclonal antibody. The invention provides a hybridoma cell strain (preservation number: CCTCC NO: C202570). A monoclonal antibody prepared from the hybridoma cell strain can be combined with VP7 protein of G6, G8 and G10 type BRVA; the antigen epitope amino acid sequence of the monoclonal antibody is SEQ ID NO: 1. The monoclonal antibody and the antigen epitope peptide provided by the invention have broad-spectrum neutralizing activity, and provide a new strategy and tool for prevention and control of BRVA.

The invention provides a construction method and application of a high-efficiency expression system based on a Seali forest virus replicon. The method comprises the following steps: constructing a saRNA system for expressing a reporter gene; constructing to obtain replicase providing plasmids in the taRNA system; constructing to obtain an antigen providing plasmid in the taRNA system; the method comprises the following steps: respectively linearizing pSFV-CMV-T7-X, pSFV-CMV-T7-TR-X and pSFV-CMV-T7-replicase, and then carrying out in vitro transcription to prepare mRNA (Messenger Ribonucleic Acid); transfecting the prepared mRNA into a host eukaryotic cell for expression according to a certain proportion to obtain an antigen protein; and detecting the antigen protein to evaluate the expression efficiency of the saRNA and taRNA system based on the SFV replicon. According to the self-amplification DNA and RNA vaccine based on the virus replicon, the development period can be shortened, and the vaccine antigen can be expressed at a high level.

The invention discloses a recombinant HVT for co-expressing an H9 subtype AIV HA gene, an IBV S gene and an IBDV VP2 gene and application of the recombinant HVT, and belongs to the technical field of medicine or veterinary medicine. The recombinant HVT is a recombinant HVT vaccine strain H30201 for co-expressing the H9 subtype AIV HA gene, the IBV S gene and the IBDV VP2 gene, which is obtained by inserting an expression cassette containing the H9 subtype AIV HA gene and the QX type IBV S gene between 95322-95323 nucleotides of an HVT FC126 strain and inserting an expression cassette containing the IBDV classic virulent strain VP2 gene between 112071-112088 nucleotides of an HVT genome at the same time through virus rescue. The invention also provides application of the recombinant HVT vaccine strain in preparation of vaccines for H9 subtype avian influenza, infectious bronchitis and infectious bursal disease.

The invention belongs to the technical field of biological products, and relates to an oil adjuvant for poultry and a preparation method thereof. The oil adjuvant for poultry comprises 5%-10% of Span, 1%-5% of Tween, 0.3%-2.0% of an AEO series surfactant, 0.1%-1.2% of a polyglycerol oleate series surfactant and the balance of white oil for injection. The poultry oil adjuvant avoids the problem of different product qualities caused by different sources of white oil, and prolongs the validity period of vaccines at the same time.

The invention belongs to the technical field of veterinary vaccines, and particularly relates to porcine rotavirus nanoparticles as well as a preparation method and application thereof. The invention provides a porcine rotavirus nano-particle. The porcine rotavirus nano-particle comprises a porcine rotavirus VP8 protein fragment, a dioxo tetrahydropteridine synthase and a linker, wherein the linker comprises a porcine rotavirus VP8 protein fragment and a dioxo tetrahydropteridine synthase; the porcine rotavirus VP8 protein fragment is connected with the dioxo tetrahydropteridine synthase through the linker, and the linker is connected with the dioxo tetrahydropteridine synthase; the amino acid sequence of the porcine rotavirus VP8 protein fragment is as shown in SEQ ID NO. 1. The porcine rotavirus nanoparticles can display more antigens at a time, so that the immunogenicity of vaccines is improved, and animals can be induced to generate higher antibody level. Results of the embodiment show that the prepared porcine rotavirus nanoparticle vaccine can cause a higher specific antibody level, and compared with a porcine rotavirus VP8 protein fragment monomer immune group, the porcine rotavirus nanoparticle vaccine can cause a higher neutralizing antibody level.

The invention discloses an antigen fusion protein and application thereof in preparation of a live vaccine for preventing infectious bursal disease. Specifically disclosed are antigen fusion proteins comprising a VP2 protein, a trimer tag, and a C3d protein. The invention also discloses recombinant Eimeria heap constructed by using the antigen fusion protein and application of the recombinant Eimeria heap in preparation of IBDV live vaccines. The oocyst of the recombinant Eimeria heap can effectively induce humoral immune response aiming at IBDV as a vaccine active ingredient, the level of an induced antibody is obviously higher than that of an insect strain expressed by a single VP2 antigen, viruses can be more effectively neutralized, the immune protection efficacy is improved, the safety is high, and the oocyst has the potential of serving as a live vector genetic engineering vaccine. The IBDV live vaccine can be orally taken through drinking water or feed, vaccination is simple, large-scale immunization of chicken flocks can be achieved, and the IBDV live vaccine is economical and efficient and has a wide prospect of being applied to prevention and control of the IBDV of the chicken flocks.

The present disclosure provides exemplary sequences and compositions that can be used to active immunization of animals to aid in the prevention of cardiomyopathy syndrome (CMS) caused by Piscine Myocarditis Virus (PMCV). Vaccines and kits comprising the sequences and compositions are also provided, as well as methods of administering the vaccine to non-human animals.

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Nucleic acids provided herein include those encoding for cancer antigens (full length proteins or fragments) as well as antibodies. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.

Disclosed herein, in certain embodiments, are non-enveloped capsid delivery systems which comprise a viral capsid polypeptide and a heterologous cargo, as well as methods of making and using such non-enveloped capsid delivery systems.

The invention relates to the technical field of aquaculture fish vaccines, in particular to a fusion gene of grass carp NPM1a and II type reovirus VP38, recombinant protein, a composition and application. The nucleotide sequence of the fusion gene is as shown in SEQ ID NO: 1. The fusion gene is obtained by connecting grass carp NPM1a and II type reovirus VP38 through a linker sequence, a BamH restriction enzyme cutting site is added to the 5'end of the fusion sequence, and an XhoI restriction enzyme cutting site is added to the 3 'end of the fusion sequence; the sequence of the linker is as shown in SEQ ID NO: 2. The subunit vaccine of the fusion protein of the grass carp NPM1a and the II type reovirus VP38 is prepared, and indole-3-lactic acid is used as an immunopotentiator in a combined manner, so that the technical bottlenecks of low protection rate, poor intestinal mucosal barrier repairability and the like of the existing vaccine are overcome.

The invention discloses a porcine rotavirus VP7 protein conservative dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application thereof, and further discloses a porcine rotavirus VP7 protein multi-epitope fusion protein and a preparation method and application thereof. The multi-epitope fusion protein disclosed by the invention not only can induce high-level specific antibody response and cellular immune response aiming at the VP7 protein and effectively inhibit porcine rotavirus infection, but also has relatively high safety and stability. Compared with the traditional fusion protein, the multi-epitope fusion protein disclosed by the invention has remarkable advantages in the aspects of production cost, immune efficacy and the like, and a feasible porcine rotavirus prevention and control scheme is provided for the pig industry.

The invention discloses a porcine group A rotavirus DNA vaccine and application thereof. The DNA vaccine is composed of an eukaryotic expression plasmid containing a G5 genotype VP7 protein gene sequence, an eukaryotic expression plasmid containing a G9 genotype VP7 protein gene sequence, an eukaryotic expression plasmid containing a P [23] genotype VP4 protein gene sequence and a TNF alpha adjuvant, the G5 genotype VP7 protein gene sequence is shown as SEQ ID NO: 1, the G9 genotype VP7 protein gene sequence is shown as SEQ ID NO: 2, and the P [23] genotype VP4 protein gene sequence is shown as SEQ ID NO: 3. The sequence of the P [23] genotype VP4 protein gene is as shown in SEQ ID NO: 3, and the sequence of the TNF alpha gene is as shown in SEQ ID NO: 4. The DNA vaccine prepared by the invention can cause remarkable humoral immunity and cellular immunity, and has a wide application prospect.

The invention relates to a Vero cell serum-free culture medium and application thereof, the serum-free culture medium is suitable for free suspension growth of Vero cells and is free of animal sources and protein components, adherent cells can be directly domesticated through a certain method to screen out Vero suspension cells, and serum-free suspension culture of the Vero suspension cells is achieved in the serum-free culture medium. The density of cells subjected to suspension culture by adopting the serum-free culture medium can reach more than 107 cells / mL, the cell viability is more than 90%, the cells are well dispersed, the cells can still normally grow and proliferate after continuous subculture for 20 generations, and the cells are sensitive to various viruses.

The invention relates to a novel fish virus, indicated to be a Totivirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.

The invention provides a porcine rotavirus type G9 (PoRV) and an application of the porcine rotavirus type G9 (PoRV). According to the present invention, the porcine rotavirus G9 type SC01 strain is separated from the porcine intestinal tract tissue, and is subjected to passage purification to obtain the porcine rotavirus G9 type SC01 strain, and the microbial preservation number of the porcine rotavirus G9 type SC01 strain is CGMCC No.46200; the isolated strain can stably proliferate on passage cells to generate typical cytopathy. The porcine rotavirus G9 type isolate has excellent immunogenicity, and a vaccine prepared from the isolate can induce piglets to generate high-level neutralizing antibodies; the ELISA kit prepared by adopting the isolated strain can be used for well detecting the porcine rotavirus G9 type antibody in serum.

The invention discloses an NDRV [sigma] C circular RNA vaccine and application thereof, and belongs to the technical field of vaccines.Duck hepatitis A virus type 1 (DHAV-1) UTR and T4 bacteriophage I type intron self-splicing cyclization systems are adopted to construct circular RNA (CirRNA-[sigma] C) for expressing NDRV [sigma] C protein, and a vaccine preparation is prepared through a chitosan-polyethyleneimine (CS-PEI) nano delivery system. The feasibility of a circular RNA vaccine system based on DHAV-1UTR in poultry vaccines is confirmed for the first time, the established nano delivery technology and circular RNA vaccine platform have the characteristics of high stability, good safety, strong immunogenicity and the like, and an important technical path is provided for development of novel vaccines of NDRV and other viral epidemic diseases.

The invention relates to the technical field of biology, and particularly discloses a recombinant vector, a recombinant baculovirus and a preparation method and application of the recombinant vector and the recombinant baculovirus. According to the method for preparing the recombinant vector, pFastBac Dual is adopted as a vector to prepare a recombinant plasmid vector inserted into a VP2 gene of an avian bursal disease virus classic strain, and the recombinant plasmid vector is named as pDual-V1; the method comprises the following steps: preparing a recombinant plasmid vector into which VP2 genes of a classical strain and a variant strain of the avian bursal disease virus are inserted at the same time, and naming the recombinant plasmid vector as pDual-V1-V2; the method comprises the following steps: preparing a recombinant plasmid vector inserted into a group I type 4 fowl adenovirus Fiber-2 gene, and naming the recombinant plasmid vector as pDual-F2; the method comprises the following steps: preparing a recombinant plasmid vector into which a Fiber-2 gene and an avian reovirus sigma C gene sequence are inserted at the same time, wherein the recombinant plasmid vector is named as pDual-F2-sigma C; carrying out double enzyme digestion on the pDual-V1-V2, recovering small fragments, carrying out double enzyme digestion on the pDual-F2-sigma C, recovering large fragments, and then carrying out mixed enzyme ligation. The recombinant baculovirus can express four antigens at the same time, and effective preparation of a multi-combined vaccine is achieved.

Disclosed are polynucleotides, and collections of polynucleotides, encoding segments of novel recombinant OSU strain rotaviruses and methods of making the same, systems for generating the same, as well as methods of using the same to elicit an immune response in a subject or to vaccinate a subject against rotavirus infection and infection.

The invention discloses a porcine rotavirus RNA vaccine and a preparation method thereof. According to the invention, amino acid sequences and nucleotide sequences of G9 type and G4 type VP4 proteins of porcine rotaviruses are optimized, and optimized translation starting elements are used, so that optimized RNA molecules with nucleotide sequences shown as SEQ ID NO.18 and SEQ ID NO.24 are finally prepared. The optimized RNA has higher immunogenicity in a mouse body. Furthermore, the porcine rotavirus RNA vaccine provided by the invention comprises a vaccine vector and the optimized RNA molecule. The porcine rotavirus G9-G4 type bivalent RNA vaccine disclosed by the invention is superior to a porcine rotavirus inactivated vaccine in the aspect of immune protection efficacy in a pig body.

The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.

The invention relates to the technical field of biology, in particular to an MDCK cell strain and application of the MDCK cell strain in preparation of influenza vaccines. The invention provides an MDCK cell strain, the preservation number of which is CCTCC NO: C202504. The cell strain not only can maintain high sensitivity and high yield to influenza viruses and ensure the yield and quality of vaccines, but also can remarkably improve the biological safety of cell matrix influenza vaccines due to elimination of tumorigenicity risk, and has a good application prospect. And a key technical support is provided for promoting domestic research and development and marketing of influenza vaccines based on cell culture.

The invention relates to a novel fish virus, indicated to be a Totivirus, which causes mortality in fish, and to methods of detecting said virus in fish, and related uses.

A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and / or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

The invention provides a subunit vaccine composition for porcine epidemic diarrhea, porcine delta coronal and porcine rotavirus as well as a preparation method and application of the subunit vaccine composition, and is characterized in that the subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants; wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of porcine epidemic diarrhea virus S protein, porcine delta coronavirus S protein and porcine rotavirus VP8 protein. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration.

A poultry vaccine against infectious bronchitis and turkey rhinotracheitis is provided. The vaccine is adjuvanted with an oil emulsion containing immunostimulatory oligonucleotides. Methods of using the vaccine are also provided. [Selection diagram] None

The invention relates to a porcine bacterial polysaccharide-viral protein conjugate vaccine as well as a preparation method and application thereof, and belongs to the technical field of animal vaccines. The vaccine takes porcine bacterial polysaccharide and virus protein as raw materials, and a polysaccharide-virus protein conjugate is formed through coupling of a biotin-avidin system; wherein the virus protein is selected from one of classical swine fever virus E2 protein, porcine circovirus type 2 Cap protein, porcine pseudorabies virus gD protein and the like, and the porcine bacterial polysaccharide is selected from one of streptococcus suis capsular polysaccharide, porcine pasteurella multocida capsular polysaccharide and the like. The vaccine can simultaneously induce an organism to generate a high-level IgG antibody aiming at porcine bacterium capsular polysaccharide and virus protein, so that synergistic immune protection on porcine bacterium and virus infection is realized, and a broad-spectrum cross immune effect is achieved.

The invention provides a recombinant Marek's disease virus co-expressing a Newcastle disease virus F gene and a novel variant VP2 gene of an infectious bursal disease virus and application of the recombinant Marek's disease virus, and belongs to the field of genetic engineering vaccines. According to the invention, by using a recombinant cloning technology, an expression framework containing a Newcastle disease virus gene VII type strain F gene and an infectious bursal disease virus novel variant VP2 gene is inserted between 105561-105563 nucleotides of a serum type 1 chicken Marek's disease virus CVI988 strain genome; according to the method, a recombinant cosmid is constructed and obtained, wherein a Newcastle disease virus F gene and an infectious bursal disease virus novel variant VP2 gene expression framework are inserted into a chicken Marek's disease virus genome, and a recombinant virus C20103 strain co-expressing the Newcastle disease virus F gene and the infectious bursal disease virus novel variant VP2 gene is rescued and obtained by the recombinant cosmid. The vaccine prepared from the recombinant chicken Marek's disease virus provided by the invention can prevent Newcastle disease, chicken infectious bursal disease and chicken Marek's disease at the same time, and has a good market application prospect.